Skip to main content

Table 1 Characteristics of the included studies

From: The association of 9p21-3 locus with coronary atherosclerosis: a systematic review and meta-analysis

Study ID

Genotyping method

SNP: and base position

Minor allele frequency

Linkage disequilibrium (LD) (reported as D’ or r2)

Population (age/(%)male/ethnicity)

Baseline diagnosis

Outcome/prognostic marker (1)

Outcome/prognostic marker (2)

Outcome/prognostic marker (3)

Comments

Anderson, [14]

with 5′ exonuclease (Taqman) chemistry on the ABI Prism 7000

rs2383206

0.48

 

1759 (59/64%/mixed race with 86% white)

CAD

No. diseased vessels

baseline Duke index

 

Prospective cohort

Chen, [15]

fluorogenic 5′ nucleotidase (Taqman) assays using an ABI PRISM® 7900 HT Real-Time PCR instrument

rs2383206 (chromosomal position: 22,105,026), rs2383207 (chromosomal position: 22,105,959), rs10757278 (chromosomal position: 22,114,477), rs1333049 (chromosomal position: 22,115,503)

rs2383206 = 0.15

D’ rs2383206 – 2383207 = 0.99

212 (48/58%/Chinese)

CAD

No. diseased vessels

  

Case control

D’rs2383206-10757278 = 1.0

D’rs2383206 – rs1333049 = 0.99

Chen, [16]

TaqMan allelic discrimination assays

rs7865618: 22021005

0.38

LD of rs7865618, rs1537378, rs1333040 with rs1333049 0.81 ≤ r2 ≤ 0.97

322 (59/84%/white)

CAD

∆MLD

no. of new lesions

 

Case control

Hoppman, [17]

TaqMan allelic discrimination assays

rs7865618: 22021005

0.38

LD of rs7865618, rs1537378, rs1333040 with rs1333049 0.81 ≤ r2 ≤ 0.97

2028 (−−/−−%/white)

CAD/ACS

All-cause mortality

Recurrent MI

revascularization

Prospective cohort

rs1537378: 22051614

0.35

rs1333040: 22073404

0.40

rs1333049: 22115503

0.49

Peng, [18]

TaqMan single nucleotide polymorphism

rs1333049

0.24

rs10757274 and rs1333049 had strong LD (r2 = 0.92)

520 (64/78.7%/Chinese)

ACS

All-cause mortality

Recurrent MI

No. diseased vessels

Case control

Newton-Cheh, [19]

Sequenom platform (San Diego, Calif), which resolves allele-specific single-base extension products using mass spectrometry (MALDI-TOF)

rs10757274 backup: rs2383207

Case: 0.54 Control: 0.50

Rs10757274 and rs2383207 are in strong linkage disequilibrium (r 2 = 0.87).

466 (−−/--%/whites)

CAD

SCD

  

Retrospective case–control study of SCD†. Subgroup analysis compared 124 SCD cases with 342 controls. Both cases and controls had CAD

Ellis, (1) [20] (CDCS)

allelespecific TaqMan genotyping probes

rs1333049

GG: 0.22

 

860 (67/69.2%/whites)

ACS

All-cause mortality

Recurrent MI

 

Cohort study

Ellis, (2) [20] (PMI)

allelespecific TaqMan genotyping probes

rs1333049

GG: 0.22

 

607 (62/78.6%/whites)

ACS

All-cause mortality

Recurrent MI

 

Cohort Study

Buysschaert, [21]

iPLEX technology on a MassARRAY

rs1333049

0.25

 

2942 (65/67.9%/whites)

ACS

Recurrent MI

  

Prospective cohort

rs7044859

rs1292136

rs7865618

Compact Analyser (Sequenom Inc., CA, USA). The WTCCC controls: Affymetrix platform (Affymetrix Inc., CA, USA).

Patel, [22]

Centaurus (Nanogen) platform

rs10757278

0.24

 

2334 (63/67%/whites)

CAD/ACS

No. diseased vessels

baseline Gensini score

 

Prospective cohort

Muehlschlegel, [23]

Golden Gate assay with an Illumina Bead Station 500G system (Illumina)

rs10116277

0.18

 

846 (−−/--%/whites)

CAD

All-cause mortality

  

Prospective cohort

Dandona, [24]

Affymetrix (Santa Clara, California) 500 K and 6.0 arrays

rs1333049

0.19

rs9632884 was linkage disequilibrium with rs1333049 (r2 = 0.832).

1714 (−−/--%/whites)

CAD/ACS

No. diseased vessels

baseline Duke index

baseline Gensini Score

case control

Liu, [25]

Golden Gate assay with an Illumina Bead Station 500 G system (Illumina, San Diego, Calif)

rs10116277

  

846 (−−/--%/whites)

CAD

Recurrent MI

  

Prospective cohort

rs6475606

rs2383207: chromosom

e 9

positions 21,930,588

22,366,970

Wang, [26]

TaqMan SNP allelic discrimination by means of an ABI 7900HT (Applied Biosystems, Foster City, CA, USA)

rs1333049

  

430 (−−/--%/Chinese)

CAD

∆MLD

no. new lesions

 

case control

Ardissino, [27]

Matrixassisted laser desorption ionization time-of-flight mass spectrometry and a Sequenome MassARRAY platform (San Diego, California)

rs1333040

  

1508 (41/95%/Italian)

ACS

All-cause mortality

recurrent MI

revascularization

Prospective cohort

Wang, [28]

TaqMan SNP allelic discrimination by means of an ABI 7900HT (Applied Biosystems, Foster City, CA, USA)

rs1333049: 9p21.3

0.25

 

620 (67/51.2%/Chinese)

CAD

No. diseased vessels

baseline Gensini score

 

Cross sectional

Chan, [29]

 

rs1333049

  

332 (59/84%/whites)

CAD

∆MLD

no. new lesions

 

Prospective cohort

Dutta, [30]

Conventional Taqman PCR (probes and assays designed by Applied Biosystems; Foster City, CA)

rs1333049

  

478 (75/--%/whites)

CAD

All-cause mortality

  

Propective cohort

Kozieradzka, [31]

TaqMan SNP Genotyping Assay using the ABI 7500 Real Time PC R System (Applied Biosystems)

rs1333049

  

582 (62/75%/--)

CAD

All-cause mortality

  

Cohort Study

rs4977574

rs10757278

Gioli-Pereira, [32]

Submicroliter PCR-based assay on array tape that is a continuous plastic tape used in conjunction with a flexible configuration of dispensing, pipetting, sealing and detection modules manufactured by Douglas Global Array

rs10757274, rs2383206, rs10757278, rs1333049

rs10757274: 0.51,

 

611 (60/84.9%/Brazilian)

CAD

All-cause mortality

No. diseased vessels

 

Prospective cohort

rs2383206: 0.59,

rs10757278: 0.51,

rs1333049: 0.48

Virani, (1) [33]

TaqMan assays

rs1333049,

CC: 0.27,

all 4 SNPs from our analyses (rs1333049, rs2383206, rs10757278, and rs10757274) have been shown to be in strong linkage disequilibrium (LD),

2067 (63/74%/whites)

ACS

All-cause mortality

recurrent MI

revascularization

Prospective cohort

CG: 0.50,

rs2383206,

GG: 0.23;

CABG group:

rs10757278, rs10757274

Virani, (2) [33]

TaqMan assays

rs1333049,

CC: 0.30,

all 4 SNPs from our analyses (rs1333049, rs2383206, rs10757278, and rs10757274) have been shown to be in strong linkage disequilibrium (LD),

1176 (65/79%/whites)

CAD

All-cause mortality

recurrent MI

revascularization

Prospective cohort

rs2383206,

rs10757278, rs10757274

CG: 0.50,

GG: 0.21;

Lill, [34]

 

rs2383206

  

452 (58/78%/--)

CAD

All-cause mortality

  

Cohort Study

  1. CAD: coronary artery disease; ACS: acute coronary syndrome; SCD: sickle-cell disease; MI: myocardial Infarction.